Nachrichten zur Pfizer Aktie

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizers GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit…

Pfizer verdient 2025 weniger - Erste Studiendaten für Gewichtssenker

NEW YORK (dpa-AFX) - Wegen eines Milliardenverlusts im Schlussquartal hat der US-Pharmakonzern Pfizer im vergangenen…

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf Neutral - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 30…

Pfizer verdient 2025 weniger - Erste Studiendaten für Gewichtssenker

NEW YORK (dpa-AFX) - Wegen eines Milliardenverlusts im Schlussquartal hat der US-Pharmakonzern Pfizer im vergangenen Jahr weniger verdient. Unter…

Pfizer Neutral

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 30…

Pfizer Aktie: 2026 wird herausfordernd

Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG:Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

Merck and Pfizer decline vs the broader market as results released

The pharma industry is handling big transitions, as highlighted in Mercks and Pfizers earnings, released Tuesday…

JPMorgan belässt Pfizer auf Neutral - Ziel 30 Dollar

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 30…

Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more

These are the stocks posting the largest moves in early trading.…

Pfizer beats fourth-quarter profit estimates on strong drug demand

Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, as sustained demand for older drugs such as blood thinner…

S&P 500 futures are little changed after index rises to start February trading: Live updates

Investors this week are digesting more than 100 S&P 500 companies posting earnings results. AMD and Pfizer are among those…

Revvity (RVTY) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateMonday, Feb. 2, 2026 at 8 a.m. ETCall participantsPresident and Chief Executive Officer — Prahlad R.…

3 Headwinds Facing Pfizer in 2026

Pfizers stock has risen off its lows, but remains 50% below its 2021 highs.…

Heres Why Pfizer Stock Is Still a Buy

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.…

Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond…

Pfizer: A High-Yield Pharma At A Turning Point

…

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks By Reuters

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical…

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks By Investing.com

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks…

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

…

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

…

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in…

Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.…

Pfizer (PFE) Outperforms Broader Market: What You Need to Know

Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.…

Novavax Aktie: Pfizer-Deal sorgt für Aufsehen

Charlotte (www.aktiencheck.de) - Novavax-Aktienanalyse der Bank of America (BofA):Die Bank of America habe das Kursziel für die Aktie von Novavax…

3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer

One of these suggested stocks features a dividend yield topping 10%.…

Novavax enters license agreement with Pfizer for vaccine development

Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.…

Down 55%, Should You Buy the Dip on Pfizer?

Pfizers stock has started to turn higher, but it is still down massively; is now the time to jump aboard?…

What to Expect From Pfizers Non-Oncology Business in Q4?

PFEs Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.…

The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)

All three of these stocks sport dividend yields above 6%.…

Pfizer: Rebound Has Just Started

…

Pfizer Aktie: Patentabläufe belasten - Kompensiert Obesity die Rückgänge wirklich?

Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG:Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

Citigroup (C) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateWednesday, Jan. 14, 2026, at 11 a.m. ETCall participantsChief Executive Officer — Jane FraserChief Financial Officer…

Pfizer (PFE) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.…

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

Novo Nordisks CEO spoke about GLP-1 pricing and Pfizers CEO spoke about the companys obesity ambitions while at the JPMorgan…

PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying…

Pfizers Patent Cliff, Rising Debt, And The Fight To Stay A Buy

…

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it…

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra By Reuters

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra…

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

MDGL Secures Exclusive Global Right for MASH Treatment From PFE

Madrigal Pharmaceuticals obtains global rights to Pfizers ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for…

Pfizers Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

This big pharma stock still faces significant challenges in the new year.…

UBS stuft PFIZER INC auf Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Pfizer mit "Neutral" und einem Kursziel von 25 US-Dollar in die…

Pfizer Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Pfizer mit "Neutral" und einem Kursziel von 25 US-Dollar in die…

This Could Be Key to Pfizers Turnaround in 2026

Pfizers been focusing on a hot area of healthcare recently: GLP-1 drugs.…

Pharma: Bayer verklagt Biontech, Pfizer und Moderna wegen Patenten von Corona-Impfstoffen

Bayer wirft mehreren Herstellern vor, eine alte Technologie kopiert zu haben, um mRNA-Impfstoffe herzustellen. Ziel sei Schadenersatz, aber kein Verkaufsverbot.…

Covid-19: Bayer verklagt Biontech und Pfizer wegen Patenten für Impfstoffe

Der Pharmakonzern Bayer wirft Pfizer, Biontech und Moderna vor, bei ihren Covid-19-Impfstoffen eine patentierte mRNA-Technologie der Bayer-Tochter Monsanto genutzt zu…